Elevating Lives for More Than 30 Years
For more than three decades, Acadia has been at the forefront of healthcare, elevating lives by providing essential solutions to those who need them most. We pioneered the first and only approved therapies for hallucinations and delusions in Parkinson’s disease psychosis and Rett syndrome. Currently, our clinical-stage developments focus on addressing Prader-Willi syndrome, Alzheimer’s disease psychosis, and neuropsychiatric symptoms in CNS disorders.
Fighting Disease So More “You” Shines Through
At Acadia, we are committed to developing therapies in areas with high unmet needs, elevating life to ensure a brighter future for all. United in our commitment, we strive for a healthier tomorrow—embracing diverse perspectives, fostering collaboration, and standing resilient in our mission to elevate life with unwavering dedication.
Latest Perspectives from Acadia
- January 24, 2025
- Acadia Story
Learn how Acadia Pharmaceuticals is redefining what's possible in neuroscience through relentless pursuit of innovation.
Innovative therapies for Parkinson’s and Rett syndrome
Advancing a treatment for Alzheimer’s disease
Committed to addressing unmet needs in rare diseases
News Releases
Patient Support
We help patients fight their diseases not only with therapies, but with support, education and connection.
Our Medicines
We have FDA-approved treatments for Parkinson’s Disease Psychosis and Rett syndrome.
Our People
We are a community of unique individuals with the mindset of a scientist, dedication of a healthcare provider and heart of a caregiver.